Back to Search Start Over

Peristomal Pyoderma Gangrenosum Responding to Risankizumab.

Authors :
Weigelt MA
Kirsner RS
Source :
Advances in skin & wound care [Adv Skin Wound Care] 2021 Jun 01; Vol. 34 (6), pp. 327-329.
Publication Year :
2021

Abstract

Abstract: Evidence to support available therapies for pyoderma gangrenosum (PG) is limited. Many patients do not respond to topical therapies such as tacrolimus or topical steroids. Currently favored oral systemic treatments (eg, cyclosporine and steroids) achieve complete remission in only 50% of patients and have unfavorable adverse effect profiles. There is a growing body of evidence to support biologic agents for the treatment of PG, but their exact role remains unclear. Here the authors present a patient with peristomal PG, the first reported case of PG responding to treatment with risankizumab, an anti-interleukin 23 monoclonal antibody. Risankizumab may represent an effective and relatively safe treatment for PG that merits additional exploration in prospective, controlled studies.<br /> (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)

Details

Language :
English
ISSN :
1538-8654
Volume :
34
Issue :
6
Database :
MEDLINE
Journal :
Advances in skin & wound care
Publication Type :
Academic Journal
Accession number :
33979822
Full Text :
https://doi.org/10.1097/01.ASW.0000744324.59877.df